Inferior outcomes in immunocompromised Merkel cell carcinoma patients: Can they be overcome by the use of PD1/PDL1 inhibitors?
- 22 June 2018
- journal article
- research article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 25 (1) , 214-216
Abstract
Cases of Merkel cell carcinoma have become increasingly more common in the last two decades, and its incidence has been predicted to climb further. Immunosenescence might explain in part the higher Merkel cell carcinoma prevalence in seniors aged 70 and older. This cancer might also be more aggressive in immunocompromised patients. In a subset of immunocompromised Merkel cell carcinoma patients, we identified significant lymphopenia and a more advanced disease stage compared with their immunocompetent counterparts. Time to death in this cohort was much shorter than in immunocompetent subjects, and their likelihood of death from Merkel cell carcinoma was five times higher. Avelumab approval in 2017 represents an important step forward in the therapy of Merkel cell carcinoma. Hopefully, PD1/PDL1 inhibitors will improve survival in immunocompromised Merkel cell carcinoma hosts, traditionally linked with inferior clinical outcomes.Keywords
This publication has 7 references indexed in Scilit:
- Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell CarcinomaJAMA Oncology, 2018
- Avelumab: A Review of Its Application in Metastatic Merkel Cell CarcinomaAnnals of Pharmacotherapy, 2018
- Merkel cell carcinoma: Current US incidence and projected increases based on changing demographicsJournal of the American Academy of Dermatology, 2018
- Immunosenescence in aging: between immune cells depletion and cytokines up-regulationClinical and Molecular Allergy, 2017
- Clinicopathologic features and survival in immunocompromised vs. immunocompetent patients with Merkel cell carcinoma: An exploratory analysis of a series of consecutive patients.Journal of Clinical Oncology, 2017
- A high neutrophil-to-lymphocyte ratio as a potential marker of mortality in patients with Merkel cell carcinoma: A retrospective studyJournal of the American Academy of Dermatology, 2016
- Absolute lymphocyte count: A potential prognostic factor for Merkel cell carcinomaJournal of the American Academy of Dermatology, 2014